Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 6/20 | 0.36 |
| ▸ | MGLL | Q99685 | 2/20 | 0.36 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.36 |
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.35 |
| ▸ | HTR2A | P28223 | 2/20 | 0.34 |
| ▸ | HTR1A | P08908 | 1/20 | 0.34 |
| ▸ | DRD2 | P14416 | 1/20 | 0.34 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.34 |
| ▸ | HTR7 | P34969 | 1/20 | 0.34 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6103192 | 0.95 | KCNH2 (0.36) | FAAHMGLLCYP4F2SIGMAR1HTR1A | |
| SCHEMBL5714886 | 0.90 | EGLN1 (0.40) | PKM | |
| SCHEMBL6100510 | 0.88 | TP53 (0.40) | FAAHMGLLCYP4F2HTR2AHTR1A | |
| SCHEMBL5715167 | 0.87 | HTR1A (0.38) | FAAHSIGMAR1HTR2AHTR1ADRD2 | |
| SCHEMBL5714840 | 0.87 | CYP4F2 (0.37) | FAAHMGLLCYP4F2SIGMAR1HTR2A | |
| SCHEMBL5715303 | 0.85 | SMN1; SMN2 (0.36) | FAAHMGLLCYP4F2SIGMAR1KCNH2 | |
| SCHEMBL5714963 | 0.84 | FAAH (0.36) | FAAHMGLLCYP4F2SIGMAR1HTR2A | |
| SCHEMBL5714878 | 0.83 | TP53 (0.44) | SIGMAR1OPRM1KCNH2 | |
| SCHEMBL6103020 | 0.83 | KDM4E (0.45) | FAAHMGLLSIGMAR1HTR2AHTR1A | |
| SCHEMBL5714647 | 0.82 | HTR1A (0.36) | CYP4F2HTR2AHTR1ADRD2KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-2006527212-A | — | — | 2006-11-30 | — | — | JP | claimed |
| US-20060160820-A1 | Substituted piperazine carbamates | NOVO NORDISK A/S (DK) | 2006-07-20 | — | — | US | claimed |
| EP-1636187-A1 | SUBSTITUTED PIPERAZINE CARBAMATES FOR USE AS INHIBITORS OF HORMONE SENSITIVE LIPASE | NOVO NORDISK A/S (DK) | 2006-03-22 | — | — | EP | claimed |
| WO-2004111004-A1 | SUBSTITUTED PIPERAZINE CARBAMATES FOR USE AS INHIBITORS OF HORMONE SENSITIVE LIPASE | NOVO NORDISK A/S (DK) | 2004-12-23 | — | — | WO | claimed |
| US-20060160820-A1 | Substituted piperazine carbamates | NOVO NORDISK A/S (DK) | 2006-07-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060160820-A1 | Substituted piperazine carbamates | LIPE, PNLIP, LPL | FAAH 219/4885MGLL 32/4885CYP4F2 1228/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.